

## LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

1-3. **(Canceled).**

4. **(Currently amended)** A method for determining whether a composition inhibits the activity of a PinI protein having the amino acid sequence set forth in SEQ ID NO: 2, said method comprising:

incubating the composition with a PinI protein having the amino acid sequence set forth in SEQ ID NO: 2 or a functional fragment thereof, wherein the functional fragment of the PinI protein has ~~protein-protein interaction~~NIMA-binding activity and/or peptidyl prolyl isomerase activity, or with a recombinant cell expressing the PinI protein or a functional fragment thereof, under conditions sufficient to allow the composition to interact with the PinI protein or functional fragment thereof; and

determining the effect of the composition on the PinI protein activity.

5-8. **(Canceled).**

9. **(Currently amended)** The method of claim 4, wherein the PinI protein activity is ~~protein-protein interaction~~NIMA-binding activity.

10. **(Previously presented)** The method of claim 4, wherein the PinI protein activity is peptidyl-prolyl isomerase activity.

11-15. **(Canceled).**

16. **(Previously presented)** The method of claim 4, wherein the functional fragment comprises at least amino acid residues 59-163 of SEQ ID NO: 2.

17. **(Previously presented)** The method of claim 4, wherein the functional fragment comprises at least amino acid residues 5-43 of SEQ ID NO: 2.

18-19. **(Canceled).**

20. **(Canceled)**——The method of claim 9, wherein the Pin1 protein activity is the binding of the Pin1 protein to a functional fragment of NIMA.

21. **(Previously presented)** The method of claim 10, wherein the peptidyl prolyl isomerase activity is not inhibited by cyclosporine A or FK520.